Delcath Systems Announces Additional $16.3 Million in Funding From Series E and E1 Warrant Exercises

Rhea-AI Summary

Delcath Systems (NASDAQ: DCTH) has secured an additional $16.3 million in funding through the exercise of 1.7 million Series E and E1 warrants. The warrants, originally issued in July and August 2019 during a private placement, had a $10.00 per share exercise price and were set to expire on December 24, 2024. Approximately 6.6% of the exercised warrants were subject to cashless exercise provisions.

CEO Gerard Michel stated that with this warrant exercise, existing cash reserves, and expected operational cash flow from revenue growth, the company is well-positioned to execute its commercialization efforts and clinical development plans for HEPZATO in treating uveal melanoma patients.

Positive

• Secured $16.3 million in additional funding through warrant exercises
• Company reports revenue growth and positive operational cash flow expectations
• Strong cash position to support commercialization and clinical development

Negative

• 6.6% of warrants exercised were cashless, reducing actual cash proceeds

Insights

Financial Analyst

The $16.3 million warrant exercise significantly strengthens Delcath's balance sheet at a important commercialization phase for HEPZATO. With 1.7 million warrants exercised at $10.00 per share, this capital injection provides essential runway for both commercial expansion and clinical development. The 93.4% cash exercise rate (versus cashless) demonstrates strong investor confidence. The timing is particularly strategic as it coincides with HEPZATO's commercial phase for uveal melanoma treatment. For a company with a $382.7 million market cap, this additional capital represents about 4.3% of their market value, providing meaningful operational flexibility without excessive dilution. The warrant conversion also simplifies the capital structure by eliminating these Series E and E1 warrants just before their December 24 expiration, improving the company's financial profile for potential future capital raises.

Market Research Analyst

This funding event reveals strong institutional confidence in Delcath's commercial trajectory. The high cash exercise rate indicates investors are willing to commit new capital rather than opt for cashless conversion, suggesting optimism about HEPZATO's market potential. The original 2019 warrants carrying a $10.00 strike price provided significant upside for early investors and their decision to exercise rather than let them expire points to positive expectations for Delcath's near-term growth. The company's focus on liver-directed therapies positions it in a specialized oncology market with competition. The additional capital strengthens their ability to expand market presence while pursuing new clinical trials, potentially broadening their addressable market beyond uveal melanoma. This dual-track strategy of commercial execution and pipeline expansion could create multiple value inflection points for investors.

QUEENSBURY, N.Y.--(BUSINESS WIRE)-- Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the exercise of 1.7 million Series E and E1 warrants which resulted in $16.3 million of funding. Approximately 6.6% of the warrants exercised were subject to cashless exercise provisions. The warrants, issued in July and August 2019 as a component of a private placement, had an exercise price of $10.00 per share and expired on December 24, 2024.

“With the exercise of these warrants, current cash on hand and cash expected from operations as a result of our revenue growth, we believe that we are in a strong position to execute on our ongoing commercialization efforts and our robust clinical development plan,” said Gerard Michel, Delcath’s Chief Executive Officer. Mr. Michel continued, “As we continue to drive the commercial success of HEPZATO to treat uveal melanoma patients we can confidently invest in new clinical trials.”

About Delcath Systems, Inc., HEPZATO KIT and CHEMOSAT

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company’s proprietary products, HEPZATO KIT^™ (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT^® Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure.

In the United States, HEPZATO KIT is considered a combination drug and device product and is regulated and approved for sale as a drug by the FDA. HEPZATO KIT is comprised of the chemotherapeutic drug melphalan and Delcath's proprietary Hepatic Delivery System (HDS). The HDS is used to isolate the hepatic venous blood from the systemic circulation while simultaneously filtrating hepatic venous blood during melphalan infusion and washout. The use of the HDS results in loco-regional delivery of a relatively high melphalan dose, which can potentially induce a clinically meaningful tumor response with minimal hepatotoxicity and reduce systemic exposure. HEPZATO KIT is approved in the United States as a liver-directed treatment for adult patients with metastatic uveal melanoma (mUM) with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation. Please see the full Prescribing Information, including BOXED WARNING for the HEPZATO KIT.

In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has been used in the conduct of percutaneous hepatic perfusion procedures at major medical centers to treat a wide range of cancers of the liver.

Safe Harbor / Forward-Looking Statements

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This press release contains forward-looking statements, which are subject to certain risks and uncertainties, that can cause actual results to differ materially from those described. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Factors that may cause such differences include, but are not limited to, uncertainties relating to: the Company’s commercialization plans and its ability to successfully commercialize the HEPZATO KIT; the Company’s successful management of the HEPZATO KIT supply chain, including securing adequate supply of critical components necessary to manufacture and assemble the HEPZATO KIT; successful FDA inspections of the facilities of the Company and those of its third-party suppliers/manufacturers; the Company’s successful implementation and management of the HEPZATO KIT Risk Evaluation and Mitigation Strategy; the potential benefits of the HEPZATO KIT as a treatment for patients with primary and metastatic disease in the liver; the Company’s ability to obtain reimbursement for the HEPZATO KIT; and the Company’s ability to successfully enter into any necessary purchase and sale agreements with users of the HEPZATO KIT. For additional information about these factors, and others that may impact the Company, please see the Company's filings with the Securities and Exchange Commission, including those on Forms 10-K, 10-Q, and 8-K. However, new risk factors and uncertainties may emerge from time to time, and it is not possible to predict all risk factors and uncertainties. Accordingly, you should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241230005270/en/

Investor Relations:

ICR Healthcare

investorrelations@delcath.com

Source: Delcath Systems, Inc.

FAQ

How much funding did Delcath Systems (DCTH) raise from warrant exercises in 2023?

Delcath Systems raised $16.3 million through the exercise of 1.7 million Series E and E1 warrants.

What was the exercise price of Delcath's Series E and E1 warrants?

The Series E and E1 warrants had an exercise price of $10.00 per share.

When were the original Series E and E1 warrants issued by DCTH?

The warrants were issued in July and August 2019 as part of a private placement.

What will Delcath Systems use the $16.3 million warrant exercise proceeds for?

The proceeds will support ongoing commercialization efforts of HEPZATO for uveal melanoma patients and fund new clinical trials.